Search company, investor...

Founded Year

1992

Stage

Acquired | Acquired

Total Raised

$13M

Valuation

$0000 

About Cubist Pharmaceuticals

Cubist Pharmaceuticals is a pharmaceutical company developing novel antimicrobial drugs.

Headquarters Location

65 Hayden Avenue

Lexington, Massachusetts, 02421,

United States

781-860-8660

Loading...

Loading...

Cubist Pharmaceuticals Patents

Cubist Pharmaceuticals has filed 65 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2014

7/19/2016

Ion channels, G protein coupled receptors, Membrane biology, Analgesics, Neurological disorders

Grant

Application Date

1/21/2014

Grant Date

7/19/2016

Title

Related Topics

Ion channels, G protein coupled receptors, Membrane biology, Analgesics, Neurological disorders

Status

Grant

Latest Cubist Pharmaceuticals News

DiaMedica Therapeutics names Masuoka as its chief medical officer

Jan 22, 2024

DiaMedica Therapeutics (NASDAQ: DMAC ) said it has appointed Lorianne Masuoka as its chief medical officer. Masuoka has more than two decades of experience, and has served as chief medical officer of firms such as Epygenix Therapeutics, Marinus Pharmaceuticals ( MRNS ), Cubist Pharmaceuticals, and Nektar Therapeutics ( NKTR ) More on DiaMedica Therapeutics

Cubist Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Cubist Pharmaceuticals founded?

    Cubist Pharmaceuticals was founded in 1992.

  • Where is Cubist Pharmaceuticals's headquarters?

    Cubist Pharmaceuticals's headquarters is located at 65 Hayden Avenue, Lexington.

  • What is Cubist Pharmaceuticals's latest funding round?

    Cubist Pharmaceuticals's latest funding round is Acquired.

  • How much did Cubist Pharmaceuticals raise?

    Cubist Pharmaceuticals raised a total of $13M.

  • Who are the investors of Cubist Pharmaceuticals?

    Investors of Cubist Pharmaceuticals include Merck & Co, Hancock Capital Management, Investors Bank And Trust Company, Clarion Capital Partners, Narragansett Asset Management and 23 more.

  • Who are Cubist Pharmaceuticals's competitors?

    Competitors of Cubist Pharmaceuticals include Biocytogen, Achillion Pharmaceuticals, Array Biopharma, PhaseBio Pharmaceuticals, Kythera Biopharmaceuticals and 7 more.

Loading...

Compare Cubist Pharmaceuticals to Competitors

G
Glycotope

Glycotope is a biotechnology company focused on developing targeted therapeutics in the oncology sector. The company specializes in creating monoclonal antibodies that recognize tumor-specific glycosylation patterns for use in cancer treatments. Glycotope's proprietary technology platform is leveraged to develop antibodies with high tumor-specificity, intended for various therapeutic applications including immuno-oncology. It was founded in 2001 and is based in Berlin, Germany.

C
Clal Biotechnology Industries

Clal Biotechnology Industries is a public investment firm targeting pre-clinical, seed, start-up, early venture, emerging growth and growth capital stages of financing that was founded in 1998 and based in Tel Aviv, Israel. Clal primarily invests in biopharmaceutical and biotech companies. Generally, Clal Biotechnogy Industries looks to invest up to $10 million per company and prefers to be lead investor and take a board seat. It also seeks to take a majority share in its portfolio companies.

C
Celgen Biopharmaceuticals

Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

7
7TM Pharma

7TM Pharma focuses on the discovery and development of drugs for metabolic diseases, including obesity and cardiovascular diseases. The company's main offerings include the development of novel treatments for obesity, such as a Y4 selective agonist and a peripherally acting CB1 antagonist designed to minimize central nervous system-related side effects. These products are primarily aimed at addressing the unmet needs for effective obesity therapies with fewer side effects. It was founded in 2000 and is based in Denmark.

O
Orabio

Founded in 2005 Ora Bio Ltd, a biopharmaceutical company, is engaged in the repositioning of existing drugs for second-use applications. nnThe Company is developing its two products, the ORA101 and ORA102, as drugs for non-small cell lung cancer (NSCLC) and age-related macular degeneration (AMD) respectively. Both the company's products are currently in Phase II clinical trials.n

E
Edunn Biotechnology

Edunn Biotechnology, Inc. is developing oligonucleotide drugs to treat central nervous system diseases. The company currently has two drugs in development. Edunn's OL-1 drug is designed to cure Alzheimer's disease and to treat Down syndrome. Per the company, it is highly selective and has shown significant activity and safety in multiple preclinical models. The company's OL-202 would be used to treat stroke and traumatic brain injury.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.